NICE Ltd each representing one Ordinary Share (NICE): Price and Financial Metrics

NICE Ltd each representing one Ordinary Share (NICE)

Today's Latest Price: $234.66 USD

0.34 (-0.14%)

Updated Nov 24 4:00pm

Add NICE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 23 in Software - Security

See all "A" rated Strong Buy stocks

NICE Stock Summary

  • With a price/earnings ratio of 80.4, NICE Ltd P/E ratio is greater than that of about 89.51% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for NICE Ltd is higher than 89.98% of stocks in our set with a positive cash flow.
  • As for revenue growth, note that NICE's revenue has grown 69.81% over the past 12 months; that beats the revenue growth of 92.59% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to NICE Ltd, a group of peers worth examining would be CHKP, ABMD, FFIV, VAR, and PTC.
  • NICE's SEC filings can be seen here. And to visit NICE Ltd's official web site, go to

NICE Stock Price Chart Interactive Chart >

Price chart for NICE

NICE Price/Volume Stats

Current price $234.66 52-week high $255.48
Prev. close $235.00 52-week low $110.59
Day low $233.00 Volume 245,400
Day high $236.56 Avg. volume 273,802
50-day MA $231.65 Dividend yield N/A
200-day MA $195.25 Market Cap 14.64B

NICE Ltd each representing one Ordinary Share (NICE) Company Bio

NICE Ltd. provides software solutions that enable enterprises and security-sensitive organizations to prevent financial crimes and fraud, ensure security and public safety, and provide enhanced customer experiences. The company was founded in 1986 and is based in Ra'anana, Israel.

NICE Latest News Stream

Event/Time News Detail
Loading, please wait...

NICE Latest Social Stream

Loading social stream, please wait...

View Full NICE Social Stream

Latest NICE News From Around the Web

Below are the latest news stories about NICE Ltd that investors may wish to consider to help them evaluate NICE as an investment opportunity.

Ergon Energy Retail selects NICE inContact CXone as cloud contact center provider

NICE (NICE) inContact CXone delivers a contact center that is scalable and also offers a wide range of applications and a full library of open application programming interfaces (APIs).CXone will help the Ergon Energy to deliver better customer support at scale through a breadth of applications and an open API library.This...

Seeking Alpha | September 15, 2020

NICE Announces Proposed Offering of $400,000,000 of Convertible Senior Notes Due 2025

HOBOKEN, N.J.--(BUSINESS WIRE)--NICE Ltd. (NASDAQ: NICE) (the "Company") announced today that it intends to offer, subject to market and other considerations, $400,000,000 aggregate principal amount of Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement under the Securities Act of 1933, as amended (the "Securities Act"). The Company also intends to grant to the initial purchasers of the Convertible Notes an option to purchase up to an additional $60,000,000 aggreg

Business Wire | August 24, 2020

Can you really beat pain without drugs?

The National Institute for Health and Care Excellence (NICE) last week warned that pills including paracetamol, should no longer be routinely prescribed to patients with chronic pain.

Daily Mail Online | August 10, 2020

NICE Ltd (NICE) CEO Barak Eilam on Q2 2020 Results - Earnings Call Transcript

NICE Ltd (NICE) Q2 2020 Earnings Conference Call August 6, 2020 8:30 AM ET Company Participants Marty Cohen - VP, Investor Relations Barak Eilam - Chief Executive Officer Beth Gaspich - Chief Financial Officer Conference Call Participants Shaul Eyal - Oppenheimer Samad Samana - Jefferies Sanjit Singh - Morgan Stanley...

SA Transcripts on Seeking Alpha | August 6, 2020

Common painkillers should not be used for chronic pain, study suggests

According to a new study, aspirin, ibuprofen and paracetamol, common painkillers we are used to taking for mild fever or aches and pains, may cause more harm than good in the treatment of chronic pain. In a draft guideline published on Monday, Aug. 3, the United Kingdom's National Institute for Health and Care Excellence (Nice) announced that there is "little or no evidence" of the efficacy of commonly used medicines against primary chronic pain, which is defined as pain that lasts or reappears for longer than three months and is caused by physical incapacity or emotional distress. According to the announcement, analgesics don't diminish pain, improve quality of life or minimiz… Keep on reading: Common painkillers should not be used for chronic pain, study suggests

Inquirer Technology | August 5, 2020

Read More 'NICE' Stories Here

NICE Price Returns

1-mo 3.33%
3-mo -0.49%
6-mo 26.07%
1-year 53.87%
3-year 172.10%
5-year 276.21%
YTD 51.25%
2019 43.38%
2018 17.73%
2017 33.92%
2016 20.93%
2015 14.29%

Continue Researching NICE

Here are a few links from around the web to help you further your research on NICE Ltd's stock as an investment opportunity:

NICE Ltd (NICE) Stock Price | Nasdaq
NICE Ltd (NICE) Stock Quote, History and News - Yahoo Finance
NICE Ltd (NICE) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9224 seconds.